CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation.

  • Year: 2012
  • Date: 2012
  • Author: Grossmann RE
Source

Eur J Clin Nutr. 2012 Sep;66(9):1072-4. doi: 10.1038/ejcn.2012.82. Epub 2012 Jul 18.

Study design (if review, criteria of inclusion for studies)

RCT

Participants

30 adults with CF hospitalized with a pulmonary exacerbation

Interventions

250 000 IU of cholecalciferol or placebo

Outcome measures

changes in plasma concentrations of inflammatory markers and the antimicrobial peptide LL-37 at baseline and 12 weeks post intervention.

Main results

In the vitamin D group, there was a 50.4% reduction in tumor necrosis factor-alpha (TNF-alpha) at 12 weeks (P<0.01), and there was a trend for a 64.5% reduction in interleukin-6 (IL-6) (P=0.09). There were no significant changes in IL-1beta, IL-8, IL-10, IL-18BP and NGAL (neutrophil gelatinase-associated lipocalin). We conclude that a large bolus dose of vitamin D is associated with reductions in two inflammatory cytokines, IL-6 and TNF-alpha.

Authors' conclusions

This study supports the concept that vitamin D may help regulate inflammation in CF, and that further research is needed to elucidate the potential mechanisms involved and the impact on clinical outcomes.

Keywords: Bacterial Infections; Exacerbation; Infection; Inpatient; non pharmacological intervention - diet; Respiratory Tract Diseases; Respiratory Tract Infections; Virus; Vitamin D; Vitamins; High-Dose; Adult; pharmacological_intervention;